Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study.

A recent study explored the effects of rimegepant for treating migraines. This trial focused on adults who cannot use triptans. Participants received a single dose of rimegepant 75 mg or a placebo. The study measured pain relief, pain freedom, and return to normal function. Researchers assessed these outcomes from 15 minutes to 48 hours after taking the medication. A total of 570 participants were included, with most being female. Many had previously tried at least two triptans without success. Results showed that rimegepant provided significant pain relief compared to placebo. Improvements were first noted as early as one hour after treatment. By 48 hours, many participants reported feeling better and returning to normal activities. This study helps understand how rimegepant works over time for those who cannot use triptans. Clinical relevance: This research highlights rimegepant's effectiveness in providing timely migraine relief for patients unable to use triptans.